Effect of the use of prediagnosis hormones on breast cancer prognosis: MCC-Spain study - Jéssica Alonso-Molero, Inés Gómez-Acebo, Javier Llorca, Virginia Lope-Carvajal, Pilar Amiano, Marcela Guevara, Vicente Martín, Gemma Castaño-Vinyals, María Fernández-Ortiz, Mireia Obón-Santacana, Juan Alguacil, Guillermo Fernandez-Tardon, Ana Molina-Barceló, Rafael Marcos-Gragera, Beatriz Pérez-Gómez - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Lippincott, Williams & Wilkins, Menopause, 11(29), p. 1315-1322, 2022

DOI: 10.1097/gme.0000000000002069

Links

Tools

Export citation

Search in Google Scholar

Effect of the use of prediagnosis hormones on breast cancer prognosis: MCC-Spain study

Journal article published in 2022 by Jéssica Alonso-Molero, Inés Gómez-Acebo, Javier Llorca, Virginia Lope-Carvajal, Pilar Amiano, Marcela Guevara, Vicente Martín, Gemma Castaño-Vinyals, María Fernández-Ortiz, Mireia Obón-Santacana, Juan Alguacil, Guillermo Fernandez-Tardon, Ana Molina-Barceló, Rafael Marcos-Gragera, Beatriz Pérez-Gómez and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO